

Biopeople Information

<https://biopeople.eu>

August 2017 PAGE 1



Contents

B4H breakfast in Malmö	P2
Causal biomarkers in dementia	P3
Meet us at Nordic Life Science days	P5
PERMIDES Funding	P6
Region Zealand project ends	P8
Calendar	P9

Produced by Biopeople
Editor Randi Krogsgaard
randi.krogsgaard@biopeople.ku.dk

BOOST4HEALTH MATCHMAKING IN MALMÖ IN SEPTEMBER

READ PAGE 2

**AGORA KEYNOTE:
CAUSAL BIOMARKERS
IN DEMENTIA**



SEE PAGE 3



**REGION ZEALAND
PROJECT ENDS**

**READ PAGE 8
IN DANISH**

Biopeople Information

<https://biopeople.eu>

August 2017 PAGE 2

BIOPEOPLE AND THE BOOST4HEALTH PROJECT INVITES FOR A MATCHMAKING BREAKFAST IN MALMØ 13 SEPTEMBER

The arrangement is held during NLS Days - Boost4Health Partner Biocat brings along a delegation from Catalonia

The Matchmaking Breakfast is open to SME's or larger biopharmaceutical companies with in interest in learning about the Boost4Health project and in exploring new opportunities for contact and collaboration cross borders.

Please feel free to join - you do not have to be attending NLS Days - Participation is free of charge but please register here

Biopeople's Catalonian partner comes with a delegation of seven companies/organisations with interests in various aspects of pharmaceutical development.

Meet for instance

- Laboratorios Rubió, S.A., which is engages in the production and distribution of pharmaceutical specialties and products for patients suffering from low prevalence diseases, including central nervous system, rheumatology, nephrology, urology, gynecology, and oncology-radiation therapy. The company offers medical devices, prescription and OTC drugs, diagnostic tests, genetic analysis, and supplements food
- ZeClinics, which is a Biotech Contract Research Organization (CRO) and early-phase biopharmaceutical (PHARMA) company using zebrafish for safety and efficacy screenings of novel chemical molecules
- Thrombotargets Europe SL, which is a privately held clinical stage biotech company that focuses on the development of new therapeutical compounds in the hemostasis and coagulation field. The company's proprietary technologies and expertise have led to an innovative pipeline. The topical hemostat TT-173, Thrombotargets lead compound, is at present in clinical Phase II
- Mind the Byte, which is a bioinformatics company specialized in computational drug discovery using big data and machine learning approaches.
- Reig Jofre, which is a pharmaceutical company focused on the research, development, manufacture and marketing of medicines and nutritional supplements, as well as on specialized manufacturing for third parties. The company specializes its R & D to develop new pharmaceutical products or variations on known active ingredients in order to modify its release, improve their dosage, get new routes of administration or indications as well as the development of generic specialties to be made and licensed by the company
- ASCIL Biopharm that develops patented injectable and locally acting therapeutics with advanced Drug Delivery Systems (DDS) -formulations and medical devices- to enhance the safety, effectiveness and convenience of administration of drugs for chronic high burden diseases



You will have a chance to meet Fira, which is one of the most important trade fair organisations in Catalonia. Fira is one of the best platforms in Catalonia for business, international exposure of companies, product marketing, networking and knowledge exchange.

We look forward to seeing you in September.

Biopeople Information

<https://biopeople.eu>

August 2017 PAGE 3



BIOMARKER AGORA 2017:

CLINICAL RESEARCH ASSOCIATE PROFESSOR AND CHIEF PHYSICIAN RUTH FRIKKE-SCHMIDT WILL OPEN THE AGORA WITH A KEYNOTE ABOUT CAUSAL BIOMARKERS IN DEMENTIA

Currently 87.000 Danish People have Alzheimer's disease. Globally the number is close to 50 million and expectations are that this number will double before 2040 due to the aging populations. At present dementia remains effectively untreatable, but new research results, which identify causal pathways of dementia, may raise the hope for future drug development

In collaboration with the University of Copenhagen's EIT Health Innovation, the opening speech at the Biomarker AGORA on 1 November 2017, is focused on aging and innovation. The research of Ruth Frikke-Schmidt Chief Physician, Rigshospitalet and Clinical Research Associate Professor, University of Copenhagen, who will open the event, is supported by EIT Health Innovation, promoting the necessary research in the causes of Alzheimer's disease.

A biomarker that mimics causal brain processes

Ruth Frikke-Schmidt recently presented a new large-scale genetic study that shows how low levels of Apolipoprotein E in the blood may be a causal risk factor for dementia. The research group has identified a marker in blood that most likely mimics causal brain processes for dementia.

106,562 blood and DNA samples examined

To examine a potential causal association between plasma levels of Apolipoprotein E and dementia, the researchers analysed blood and DNA samples from 106,562 participants in the Copenhagen General Population Study (CGPS) and the Copenhagen City Heart Study.

"We analysed the study participants' DNA for the presence of five genetic variants that have strong associations with blood levels of Apolipoprotein E. Based on how

Biopeople Information

<https://biopeople.eu>

August 2017 PAGE 4

many variants we found, we divided the participants into four groups to reflect the likelihood of low blood levels of Apolipoprotein E. The results showed that the presence of genetic variants tied to low Apolipoprotein E was associated with increased risk of dementia," says Ruth Frikke-Schmidt and continues: "This makes absolutely biological sense since Apolipoprotein E is a key molecule for removing the sticky β -amyloid compound, which is what senile plaques in dementia consist of. When Apolipoprotein E levels are low in the brain, the molecule less effectively remove the β -amyloid. This most likely explains the increased risk of dementia."

Increased risk with lifelong low Apolipoprotein E

The research group found that individuals with lifelong low Apolipoprotein E in the blood due to genetic variation were at increased risk of developing dementia. Since genetic variants are not affected by other risk factors or diseases, this is a clean measure that can help to determine the causality of dementia. "The findings highlight that testing causality of a risk factor, in this case levels of Apolipoprotein E in the blood, is pivotal for successful drug development. If the molecules selected for drug development are not causal, the drugs will not work, or do harm," Ruth Frikke-Schmidt says.

Collaboration and support

Ruth Frikke-Schmidt conducted the project in collaboration with MD, PhD Katrine Laura Rasmussen, Rigshospitalet and Herlev and Gentofte Hospital, and professor, MD, DMSc Anne Tybjerg-Hansen, Rigshospitalet, and professor, MD, DMSc Børge G. Nordestgaard, Herlev and Gentofte Hospital. The Danish Council of Independent Research, the Research Council at Rigshospitalet, and The Lundbeck Foundation supported the research project.

The article on the Study is in press: "Plasma Apolipoprotein E levels and risk of dementia—A Mendelian randomization study of 106,562 individuals" is available online by Alzheimer's & Dementia: The Journal of the Alzheimer's Association.

Alzheimer's facts and figures

More than 5 million Americans have Alzheimer's disease – the most common form of dementia - according to the Alzheimer's Association 2017 Alzheimer's Disease Facts and Figures Report.

The prevalence of dementia is anticipated to double from now and until 2040 (Ahmadi-Abhari S et al. BMJ 2017;358:j2856: doi:10.1136/bmj.j2856).

Read more about Ruth Frikke-Schmidts research



"Our findings highlight that testing causality of a risk factor, in this case levels of Apolipoprotein E in the blood, is pivotal for successful drug development. If the molecules selected for drug development are not causal, the drugs will not work, or do harm," Ruth Frikke-Schmidt says.

Biopeople Information

<https://biopeople.eu>

August 2017 PAGE 5



MEET US AT NORDIC LIFE SCIENCE DAYS 2017

Biopeople will be present at Nordic Life Science Days, sharing an exhibition stand with Medicon Valley Alliance and Swedish Medeo

We are all facilitating professional networking in the Medicon Valley (Greater Copenhagen) region and will together represent this profession at the Nordic Life Science Days.

This means that we want to meet and network with as many people as possible during the conference days and what is better than starting with a reception?

This reception takes place on 12 September 2017 between 2 and 5 p.m. at our exhibition stand - booth number C05 - please join us in celebrating a good collaborative framework in Medicon Valley.

Floor plan for download here - look for the yellow mark

Biopeople Information

<https://biopeople.eu>

August 2017 PAGE 6



PERMIDES – FUNDING FOR INNOVATION PARTNERSHIPS TO DIGITALIZE BIOPHARMACEUTICAL R&D

Open Call Announcement: Biopharma SMEs can avail benefits from this call for obtaining vouchers up to a maximum of € 60,000.

Deadline 10 October 2017

The EU project PERMIDES, which provides innovation vouchers for biopharma SMEs valued up to 60,000 € for cooperation projects with IT companies.

PERMIDES aims at bringing together SMEs from the biopharmaceutical and IT sector to advance precision medicine through the development of novel digital solutions along the biopharmaceutical value chain.

Danish Biopharma companies may benefit from the financial support of the vouchers. Biopharma companies are e.g. active in the area of biotech / medtech, diagnostics, contract research, biobanks and bioinformatics etc.

PERMIDES receives funding from the EU Horizon 2020 programme, the project is coordinated by CyberForum. Overall a budget of about 3 million € will be handed out via innovation vouchers.

In the first application period 22 projects totalling about 1.3 million € were funded.

Interested SMEs can still apply for financial support at <http://permides.eu/> until 10 October 2017

The application process is very unbureaucratic so SMEs can easily participate.

Please find further information about the application process at: <http://permides.eu/how-to>

Read more about the call

Biopeople Information

<https://biopeople.eu>

August 2017 PAGE 7

IT SMEs can collaborate with various biopharma SMEs in multiple projects, and are not affected by € 60,000 limit. Please note that biopharma SMEs are the beneficiaries of the innovation projects and the costs involved in providing the services by IT SMEs will be funded and paid to IT SMEs by PERMIDES.

About PERMIDES

It is the aim of PERMIDES to strengthen the competitiveness and foster the innovation potential of Personalized Medicine as an Emerging Industry in Europe by providing key solutions for the reconfiguration of the biopharmaceutical value chain towards a Health Economy 4.0 with a special focus on oncology (i.e. cancer treatment). Current value chain challenges lie in e.g. data gathering and exchange, big data and machine learning, or new software-based marketing methods based.

Via a cross-clustering approach, leading biopharma and IT clusters from three countries (Austria, Germany and Norway) will create novel cross-sectoral collaborations between SMEs to address innovation barriers in the biopharma sector via cutting-edge IT solutions. As a cross-cutting industry, the ICT and software sector is an enabler of innovation in many industries and therefore provides a broad knowledge base of processes and best practice solutions in diverse industrial contexts and business environments.

Biopeople Information

<https://biopeople.eu>

August 2017 PAGE 8



PROJEKTET: KVALIFICERET ARBEJDSKRAFT I REGION SJÆLLAND HOLDER AFSLUTNINGSKONFERENCE

Region Sjælland ønsker at øge tilgængeligheden af den rette og kompetente arbejdsstyrke til virksomhederne herunder udbuddet af kvalificeret arbejdskraft regionalt.

Dette er baggrunden for projektet: "Kvalificeret arbejdskraft til produktionsvirksomheder i Region Sjælland" (KAP), som skal bidrage til en stærkere sammenhæng mellem uddannelse, kompetence, beskæftigelse og virksomhedernes behov. Målgruppen for KAP har været unge uddannelsessøgende i Region Sjælland og Sjællandske produktionsvirksomheder.

KAP startede i 2015, finansieret via en bevilling på 2 millioner kr. fra Region Sjælland samt i alt 2 millioner kr. i form af arbejdstimer fra de virksomheder, der deltog i projektet.

Den 11 oktober 2017 afsluttes projektet med en konference på Ringsted Kongrescenter, hvor produktionsvirksomheder i Region Sjælland, de regionale erhvervsråd, og de regionale uddannelsesinstitutioner, herunder lærere og studerende er inviteret til at høre om projektet og indgå i dialog om evt. fremtidige samarbejdsrelationer.

På konferencen vil regionsformand, Jens Stenbæk, Region Sjælland fortælle om projektet, Claus Astrup Seidelin, Senior Økonom i DEA kigger på det regionale projekt i overordnet perspektiv, og studerende, lærere og virksomheder går på podiet og fortæller om erfaringer fra de konkrete samarbejdsprojekter i projektperioden.

Deltagerne får desuden lejlighed til at stille spørgsmål direkte til de virksomheder, lærerne og de studerende, der indgår i projektet samt udforske mulighederne for at etablere nye frugtbare samarbejder, der kan fostre nye medarbejdere, nye kompetencer og ideer, vækst og innovation.

Læs mere på projektsiden
www.kap-sjaelland.dk

Calendar

<https://biopeople.eu>

August 2017 PAGE 9

11 September 2017	Personalized Medicine & Biomarkers - H2020 Health Brokage Event
12 September 2017	Nordic Life Science Days 2017, Malmö
12 September 2017	Welcome Reception at the Medicon Valley Alliance, Medeon and Biopeople stand (NLS Days)
13 September 2017	Biopeople and Biocat (Barcelona) welcome you to Boost4Health Matchmaking Breakfast in Malmö
14 September 2017	Workshop: Greater Copenhagen Life Science and Cleantech Clusters meets The Four Motors for Europe
17 September 2017	Business Delegation to Israel
19 September 2017	Etiske overvejelser ved patientdeltagelse i afprøvning af lægemidler
2 October 2017	Copenhagen Centre for Regulatory Science 3rd Annual Conference
10 October 2017	BIOTECH Cluster SME Mission & BioJapan, Japan (EU Delegation)
10 October 2017	Hospital + Innovation Congress
10 October 2017	WHIIN
11 October 2017	Afslutningskonferenve KAP Sjælland
1 November 2017	Biomarker AGORA 2017
6 November 2017	BIO-Europe® 2017 - 23rd Annual International Partnering Conference
27 November 2017	Future Week Denmark
27 November 2017	Fundingmuligheder i EU til MedTech og BioTech
22 January 201	Training Course in Safety Sciences - Regulatory Requirements and Guidelines (IMI SafeSciMET), Lisbon